Occurrence of chlamydial cervicitis in Upper Silesia, Poland  by Friedek, D. et al.
Acinetobacter infection, and received a second
course of colistin–rifampicin; two of these patients
died (one from carbapenem-resistant A. baumannii
ventilator-associated pneumonia and candidae-
mia, and the other from Pseudomonas ventila-
tor-associated pneumonia). Thus, therapy with
colistin–rifampicin, and with ampicillin–sulbac-
tam in case of susceptibility to this combination,
resulted in microbiological clearance of carbape-
nem-resistant A. baumannii infection in nine (64%)
of 14 critically-ill patients, with limited side-
effects. Although the limited number of patients,
and the lack of a control group, in this series does
not allow a definite conclusion, it seems that the
combination of colistin and rifampicin may be an
innovative therapeutic option for consideration in
the treatment of severe infections caused by
carbapenem-resistant A. baumannii.
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Occurrence of chlamydial cervicitis in
Upper Silesia, Poland
The recent article in Clinical Microbiology and
Infection by Kese et al. [1] described a prevalence
of Chlamydia trachomatis infection of 19.5% in
male partners and of 10.7% in female partners
attending two sexually transmitted disease clinics
in Slovenia. The study used two diagnostic
methods for the detection of C. trachomatis,
namely the MicroTrak direct fluorescent antibody
test, followed by the Amplicor PCR assay if the
direct fluorescent antibody results were inconclu-
sive. The results of the study supported the
implementation of routine screening for C. tracho-
matis genital infection among male and female
patients aged < 30 years who attend sexually
transmitted disease clinics in Slovenia.
It is well-known that the level of chlamydial
cervicitis decreases quickly in countries where
routine screening for C. trachomatis is mandatory
[2,3]. In Poland, routine screening for C. tracho-
matis is not yet provided. Our own experience in
Upper Silesia (south Poland; population c. 5
million) demonstrated a chlamydial aetiology for
cervicitis in 173 (49.3%) of 351 sexually active
women (mean age 31.7 ± 6.82 years) attending
the Department and Clinic of Gynaecology and
Endocrinology at the Medical University of
Silesia, Katowice, between 2001 and 2004. All
351 women had symptoms of cervicitis, i.e.,
mucopurulent endocervical discharge and ⁄ or
‡ 30 neutrophils in a ·1000 field on the cervical
Gram stain, and ⁄ or bleeding. C. trachomatis was
detected by the direct immunofluorescence assay
(bioMe´rieux, Marcy l’Etoile, France), performed
according to the manufacturer’s instructions.
There was a significant difference between the
prevalence of C. trachomatis in Katowice (49.3%)
and the study of Kese et al. (10.7%) [1]. However,
Kese et al. [1] studied patients without clinical
symptoms of cervicitis attending sexually trans-
mitted disease clinics, while the Katowice study
only included patients with clinical symptoms of
cervicitis. In addition, there were differences in
the methods used for the detection of C. tracho-
matis. The direct immunofluorescence assay is a
rapid assay, but is less sensitive than the nucleic
acid amplification techniques, which are accep-
ted currently as the standard for diagnosis of
C. trachomatis infection and which were used by
Kese et al. [1] when inconclusive results were
obtained with the direct fluorescent antibody test.
Nucleic acid amplification techniques demon-
strate a sensitivity and specificity of 56–100%
and > 99%, respectively, in comparison with cell
culture [4]; in contrast, the reported sensitivity
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and specificity of the direct immunofluorescence
method are 50–90% and > 95%, respectively.
The direct immunofluorescence method is still
often used for detection of C. trachomatis in
Poland. In a separate study using this method in
northern Poland [5], a similar relatively high
percentage (39.2%) of chlamydial cervicitis was
demonstrated, although another Polish study [6]
demonstrated a somewhat lower percentage of
chlamydial cervicitis (18.4%) using the same
method. In Katowice, cervical ectopia was con-
firmed in 26.5% (93 ⁄ 351) of the women examined,
and ectopia was associated with cervical chlamy-
dial infection in 42 cases, although the prevalence
of ectopia among women with chlamydial and
non-chlamydial cervicitis was similar (24.3% vs.
28.7%, respectively; p < 0.05). The possible inter-
dependence of cervical ectopia and C. trachomatis
must be analysed carefully because of the diffi-
culty in deciding whether ectopia is a predispo-
sing factor for C. trachomatis infection, or whether
the infection process started by chlamydia leads
to cervical ectopia [5,7,8]. However, the results
obtained suggest that the presence of cervical
ectopia indicates the importance of looking for
C. trachomatis.
The results from Upper Silesia demonstrate the
importance of C. trachomatis screening, especially
in the group aged < 30 years. We agree with Kese
et al. [1] that early diagnosis and appropriate
treatment of chlamydial cervicitis among the
younger population will help to prevent eventual
severe complications emerging in older age
groups. There appears to be a high frequency of
C. trachomatis infection among women with cer-
vicitis in Upper Silesia, thereby indicating a
requirement to implement routine screening for
these organisms.
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